Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2019

Reina-Campos M, Linares JF, Duran A, Cordes T, L'Hermitte A, Badur MG, et al. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer. Cancer Cell. 2019;35(3):385-400.e9.

Cohn CS, Allen ES, Cushing MM, Dunbar NM, Friedman DF, Goel R, et al. Critical developments of 2018: A review of the literature from selected topics in transfusion. A committee report from the AABB's Clinical Transfusion Medicine Committee. Transfusion. 2019;59(8):2733-2748.

Canver MC, Satlin MJ, Westblade LF, Kreiswirth BN, Chen L, Robertson A, et al. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(9).

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.

Ahmed A, Crowson N, Magro CM. A comprehensive assessment of cutaneous Rosai-Dorfman disease. Ann Diagn Pathol. 2019;40:166-173.

Cross T, Ransegnola B, Shin J-, Weaver A, Fauntleroy K, VanNieuwenhze MS, et al. Spheroplast-Mediated Carbapenem Tolerance in Gram-Negative Pathogens. Antimicrob Agents Chemother. 2019;63(9).

Hirsch Y, Zeevi DA, Lam BL, Scher SY, Bringer R, Cherki B, et al. A founder deletion in the TRPM1 gene associated with congenital stationary night blindness and myopia is highly prevalent in Ashkenazi Jews. Hum Genome Var. 2019;6:45.

Jin C, Huang Y, Nasim M, Yang Y, Lee L. Gastrointestinal Stromal Tumors Risk Stratification Utilizing Phospho-Histone H3 Evaluated by Manual Counting and Computer-Assisted Image Analysis. Int J Surg Pathol. 2019;27(7):706-712.

Melis M, Tang X-, Trasino SE, Patel VM, Stummer DJ, Jessurun J, et al. Effects of AM80 compared to AC261066 in a high fat diet mouse model of liver disease. PLoS One. 2019;14(1):e0211071.

Gomez-Arteaga A, Margolskee E, Wei MT, Van Besien K, Inghirami G, Horwitz S. Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leuk Lymphoma. 2019;60(7):1626-1631.